{"id":17761,"date":"2022-10-19T16:24:33","date_gmt":"2022-10-19T14:24:33","guid":{"rendered":"https:\/\/www.curus.se\/nyheter\/new-drug-drives-demand-for-geras-solutions-digital-alzheimers-diagnostic-tool\/"},"modified":"2022-10-19T16:24:33","modified_gmt":"2022-10-19T14:24:33","slug":"new-drug-drives-demand-for-geras-solutions-digital-alzheimers-diagnostic-tool","status":"publish","type":"post","link":"https:\/\/www.curus.se\/en\/nyheter\/new-drug-drives-demand-for-geras-solutions-digital-alzheimers-diagnostic-tool\/","title":{"rendered":"New drug drives demand for Geras Solutions&#8217; digital Alzheimer&#8217;s diagnostic tool"},"content":{"rendered":"<p><strong>Swedish med-tech and healthcare company Geras Solutions is one of the most exciting companies in dementia and Alzheimer&#8217;s diagnostics.<br \/>\nThey are unique in the world in enabling early diagnosis through fully cognitive assessments digitally &#8211; from home. <\/strong>  Dementia currently affects more than 50 million people worldwide and the number is increasing rapidly as the population ages.<br \/>\nHealthcare systems have long struggled with limited capacity, poor patient access and lack of continuity.<br \/>\nThe recent news of significant breakthroughs in the treatment of Alzheimer&#8217;s disease also brings new demands on health systems.<br \/>\nThe need to ensure that treatable patients are identified in a timely manner, while coping with the increased demand for assessments from people suffering from memory loss, is more urgent than ever.<br \/>\nGunilla Oswald, CEO of BioArctic, the company behind the new Lecanumab treatment, said of Geras Solutions: &#8211;      <em>The introduction of disease-modifying therapies will bring new hope to patients suffering from Alzheimer&#8217;s disease.<br \/>\nEarly detection through digital cognitive tests and blood-based biomarkers will be crucial, and all stakeholders who can offer a new way to improve quality, efficiency and patient access have an important role to play. <\/em>  Geras Solutions&#8217; platform is now being implemented by both public and private healthcare providers.<br \/>\nThe company also launches the world&#8217;s first digital memory clinic, which is now receiving state reimbursement in Sweden as of mid-October.<br \/>\nGeras Solutions is now opening a \u20ac1.5 million seed round to intensify go-to-market and scale up operations. &nbsp;<strong>If there is interest in participating in this round, please contact:<\/strong> Rickard Forsman, Founder and CEO of Geras Solutions <a href=\"mailto:rickard.forsman@gerassolutions.com\">rickard.forsman@gerassolutions.com<\/a> See pitch for Geras solution <a href=\"https:\/\/addhealthmedia.com\/wp-content\/uploads\/2022\/10\/Geras-Solutions_investor-pitch_2022.pdf\">here<\/a>  <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Swedish med-tech and healthcare company Geras Solutions is one of the most exciting companies in dementia and Alzheimer&#8217;s diagnostics. They are unique in the world in enabling early diagnosis through fully cognitive assessments digitally &#8211; from home. Dementia currently affects more than 50 million people worldwide and the number is increasing rapidly as the population [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":16211,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[301,312,302,306,314,303,304],"tags":[],"class_list":["post-17761","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-e-halsa-en","category-innovation-en-2","category-intressebolag-en","category-investment-en-2","category-news-en-3","category-nyheter-en","category-pressmeddelande-en"],"_links":{"self":[{"href":"https:\/\/www.curus.se\/en\/wp-json\/wp\/v2\/posts\/17761","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.curus.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.curus.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.curus.se\/en\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/www.curus.se\/en\/wp-json\/wp\/v2\/comments?post=17761"}],"version-history":[{"count":0,"href":"https:\/\/www.curus.se\/en\/wp-json\/wp\/v2\/posts\/17761\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.curus.se\/en\/wp-json\/wp\/v2\/media\/16211"}],"wp:attachment":[{"href":"https:\/\/www.curus.se\/en\/wp-json\/wp\/v2\/media?parent=17761"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.curus.se\/en\/wp-json\/wp\/v2\/categories?post=17761"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.curus.se\/en\/wp-json\/wp\/v2\/tags?post=17761"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}